Form 4: Cara Therapeutics Director Ives Receives Stock Options and Restricted Stock Units

Director Jeffrey L. Ives receives stock options and restricted stock units from Cara Therapeutics, Inc.

Summary

• On June 4, 2024, Jeffrey L. Ives, a director of Cara Therapeutics, Inc., was granted 150,647 restricted stock units (RSUs) and an option to purchase 195,000 shares of common stock.
• The RSUs represent the contingent right to receive one share of common stock each.
• The options have an exercise price of $0.664 per share and expire on June 4, 2034.
• Both the RSUs and the options vest on the earlier of June 4, 2025, or immediately prior to the Issuer's next annual meeting of stockholders following the grant date, subject to continued service as a director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard director compensation practices, aligning interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

This type of equity compensation is common for directors of publicly traded companies to align their interests with shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash and equity.
• The size of the grant is likely benchmarked against peer companies in the biotechnology industry to attract and retain qualified board members.
• Vesting schedules are standard practice to ensure continued service and alignment with long-term company performance.

Stakeholder Impact

• The grant of equity to a director can be viewed positively by shareholders as it aligns their interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates